Fluticasone furoate: CAPTAIN of fluticasones in type 2 inflammatory asthma

Simon Couillard, Ian D Pavord, Simon Couillard, Ian D Pavord

No abstract available

Keywords: CAPTAIN study; FeNO; asthma; eosinophils; fluticasone furoate; inflammatory; inhaled corticosteroid; nitric oxide; respiratory function test.

References

REFERENCES

    1. Daley-Yates PT. Inhaled corticosteroids: potency, dose equivalence and therapeutic index. Br J Clin Pharmacol. 2015;80(3):372-80.
    1. Daley-Yates P, Brealey N, Thomas S, Austin D, Shabbir S, Harrison T, et al. Therapeutic index of inhaled corticosteroids in asthma: a dose-response comparison on airway hyperresponsiveness and adrenal axis suppression. Br J Clin Pharmacol. 2021;87(2):483-93.
    1. Zhong Y, Chen R, Li L, Zheng Q. Quantitative comparison of dose-effect and time-course of fluticasone furoate and fluticasone propionate in adult and adolescent patients with persistent asthma: a systematic review and meta-analysis. Respirology. 2022;27(3):194-201.
    1. Beasley R, Harper J, Bird G, Maijers I, Weatherall M, Pavord ID. Inhaled corticosteroid therapy in adult asthma time for a new therapeutic dose terminology. Am J Respir Crit Care Med. 2019 Jun 15;199(12):1471-7.
    1. Pavord ID, Beasley R, Agusti A, Anderson GP, Bel E, Brusselle G, et al. After asthma: redefining airways diseases. Lancet. 2018;391:350-400.
    1. Lee LA, Bailes Z, Barnes N, Boulet L-P, Edwards D, Fowler A, et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med. 2021;1:69-84.
    1. Couillard S, Shrimanker R, Chaudhuri R, Mansur AH, McGarvey LP, Heaney LG, et al. Fractional exhaled nitric oxide nonsuppression identifies corticosteroid-resistant type 2 signaling in severe asthma. Am J Respir Crit Care Med. 2021;204:731-4.
    1. Couillard S, Laugerud A, Jabeen M, Ramakrishnan S, Melhorn J, Hinks TSC, et al. Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide. Thorax. 2022;77:199-202. Available from:
    1. Couillard S, Do W, Beasley R, Hinks T, Pavord I. Predicting the benefits of type-2 targeted anti-inflammatory treatment with the prototype OxfoRd Asthma attaCk risk scaLE (ORACLE). ERJ Open Res. 2022;

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren